-1.png?width=1800&height=1000&name=Home%20Testing%20Blog%20(3)-1.png)
.png?width=1200&height=628&name=Week%20of%207th%20April%20(50).png)
GLP1s
Women's weight loss UK
Tirzepatide UK
Oral GLP-1 obesity treatment
Orforglipron
oral GLP-1
Foundayo (Orforglipron): The Oral GLP-1 Pill Approved in the US - When Is It Coming to the UK?
.png?width=48&height=48&name=Untitled%20design%20(23).png){kind=small}
TribeTeam
Breaking news update!
- Foundayo (orforglipron) was FDA approved in the US on 1 April 2026
- It is now available in US pharmacies and via LillyDirect
- It is not yet approved by the MHRA in the UK
- MHRA submission is underway; UK availability is estimated late 2026 to 2027 for private, 2027+ for NHS
Obesity affects nearly 1 in 4 UK adults and is one of the country's fastest-growing health challenges. GLP-1 therapies like Wegovy and Mounjaro have transformed weight-loss care, but they're injectable, and that's not ideal for everyone. Needles, cold storage, injection anxiety, for many people, the barriers are real.
Meet Orforglipron.
A once-daily oral pill showing real promise as an alternative to injectable GLP-1s.
💊 Once-Daily Oral Pill 🔬 Phase 3 Trials UK Relevant ⏳ Expected 2026
What UK-Relevant Trials Show
Phase 3 ATTAIN-1: Obesity Without Diabetes
The ATTAIN-MAINTAIN trial, which enrolled over 4,500 people across the full ATTAIN programme, tested whether people who had already lost weight on injectable GLP-1s could switch to oral orforglipron for long-term maintenance.
Participants who had reached a weight plateau on injectable Wegovy or Mounjaro were re-randomised - this is a hugely relevant finding for UK women already on injectables who are watching this space.
At 72 weeks, participants taking the highest daily dose lost an average of:
12.4%
of their body weight (~12.4 kg / 27.3 lbs)
vs just 0.9% for placebo
~60%
lost at least 10% of body weight
~40%
lost 15% or more
Participants also saw improvements in cardiovascular risk markers, including cholesterol and blood pressure, suggesting clinically meaningful effects beyond weight loss alone.
Phase 2 Evidence: The NEJM Data
Earlier Phase 2 data published in The New England Journal of Medicine found orforglipron achieved 8.6%–14.7% average weight loss over 36 weeks, significantly outperforming placebo (~2%).
The trial also showed dose-dependent effects on waist circumference and meaningful reductions in BMI and metabolic risk factors, paving the way for the full Phase 3 programme.
The US launch - what it tells us
- FDA approved 1 April 2026 under the brand name Foundayo
- Available via LillyDirect, telehealth providers and US retail pharmacies, with prescriptions accepted immediately from 6 April PR Newswire
- Eligible people with commercial insurance in the US may pay as little as $25 per month; self-pay starts at $149 per month for the lowest dose. This is useful us in the UK readers thinking about what pricing might look like, PR Newswire
- this is the first small-molecule oral GLP-1 for weight loss to reach the market anywhere in the world!
Side Effects & Practical Considerations
Orforglipron is designed to be taken once daily without fasting or fluid restrictions, which can be easier for many patients than some oral GLP-1 options that require specific timing with meals.
The most commonly reported side effects are gastrointestinal, typically during dose escalation:
🤢 Nausea
🚽 Diarrhoea
😔 Vomiting
These are consistent with the GLP-1 class overall; severity varies by dose and individual tolerance.
Regulatory Status
Any UK website currently claiming to sell orforglipron is not operating legally.
How does Foundayo compare to what's available now in the UK?
- Foundayo vs Mounjaro: both Eli Lilly, but Mounjaro is injectable + dual GIP/GLP-1 vs Foundayo's oral GLP-1 only; Mounjaro shows higher average weight loss (~20% vs ~12%)
- Foundayo vs Wegovy: both GLP-1 only; Wegovy injectable; the oral Wegovy pill (oral semaglutide) is expected to reach the UK sooner, with approval anticipated in late 2026 - if you want an oral GLP-1 option as soon as possible, the Wegovy pill is likely to be the first available in the UK
- While waiting for Foundayo, Mounjaro and Wegovy are available now through GPhC-registered pharmacies, including TribElle
Why This Matters for the UK
💉
A Pill Could Increase Accessibility
Injectable GLP-1s are proven, but needle aversion, storage requirements, and costs create real barriers. An oral alternative could be easier to integrate into everyday life.
🏥
NHS & Private Prescribing Options
If approved, orforglipron may join the UK's obesity treatment toolkit alongside Mounjaro, Wegovy and Saxenda, giving clinicians more tailored options for their patients.
📊
Public Health Impact
Given the link between obesity and type 2 diabetes, heart disease, and other chronic conditions, more accessible therapies with strong efficacy could meaningfully reduce the long-term burden on the NHS.
FAQs About Orforglipron in the UK
What is Foundayo?
The US brand name for orforglipron, an oral once-daily GLP-1 pill for weight loss, approved by the FDA on 1 April 2026
Is orforglipron available in the UK?
Not yet. MHRA review is underway; realistic UK availability is late 2026 for private prescribing, 2027+ for NHS
How does orforglipron compare to Mounjaro?
Both are from Eli Lilly. Mounjaro is injectable and targets both GLP-1 and GIP receptors with higher average weight loss. Orforglipron is oral, targets GLP-1 only, and showed around 12.4% average weight loss at the highest dose
Can I buy orforglipron in the UK now?
No. It is not licensed in the UK. Any UK site claiming to sell it is not operating legally
Can I buy orforglipron in the UK now?
No - this is one of its key advantages. It can be taken any time of day without food or water restrictions
What can I take now while waiting?
Mounjaro and Wegovy are both MHRA-approved and available now through regulated pharmacies
Who should not take orforglipron?
Anyone with a personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2 should not take it
Orforglipron could change what weight management looks like for millions.
we're a GPhC-registered pharmacy and we'll be among the first to offer Foundayo once MHRA approval comes through.
Your Tribe Is Here
We're building a bigger, stronger tribe for women, a space where you're seen, heard, and supported in navigating your health journey.
Because every woman deserves healthcare that sees her, hears her, and heals her.
Join the conversation
You don't have to go through this alone
|
|||
|
-1.png?width=1800&height=1000&name=Home%20Testing%20Blog%20(7)-1.png)